Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial
Autor: | Helge Bischoff, Jürgen Debus, Uwe Haberkorn, Klaus Herfarth, Peter E. Huber, Marc W. Münter, Michael Thomas, Alexandra D Jensen, Renate Haselmann |
---|---|
Rok vydání: | 2010 |
Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Cetuximab Comorbidity Antibodies Monoclonal Humanized Disease-Free Survival Internal medicine Carcinoma Non-Small-Cell Lung medicine Humans Stage (cooking) Pneumonitis Aged Neoplasm Staging Aged 80 and over business.industry Cancer Antibodies Monoclonal Radiotherapy Dosage Middle Aged Radioimmunotherapy medicine.disease Combined Modality Therapy Acute toxicity Radiation therapy Survival Rate Regimen Positron-Emission Tomography Female Radiotherapy Intensity-Modulated business medicine.drug |
Zdroj: | Cancer. 117(13) |
ISSN: | 1097-0142 |
Popis: | BACKGROUND: The aim of this study was to evaluate efficacy and toxicity of radioimmunotherapy with intensity-modulated radiation (IMRT) and cetuximab in stage III nonsmall cell lung cancer (NSCLC). METHODS: NEAR was a prospective, monocentric phase II trial including patients unfit for chemoradiation regimen; treatment consisted of IMRT and weekly cetuximab followed by a 13-week maintenance period. Primary endpoints were toxicity and feasibility; secondary endpoints were remission rates at completion of the planned treatment according to Response Evaluation Criteria In Solid Tumor (RECIST), local/distant progression-free survival, and overall survival. RESULTS: Thirty patients (median age, 71 years) were treated within the protocol. Overall response rate was 63% (partial remission: 19 of 30) patients. Median locoregional, distant, overall progression-free survival was 20.5, 10.9, and 8.5 months. Median overall survival was 19.5 months, with an estimated 1- and 2-year survival of 66.7% and 34.9% respectively. Stage (IIIA vs IIIB) and histologic subtype did not have a significant impact on survival rates in our patients. Treatment was tolerated well with only mild toxicity (°3 pneumonitis: 3.3%, any °3 acute toxicity: 36.7%). CONCLUSIONS: Combined radioimmunotherapy with cetuximab was safe and feasible, especially in elderly patients with multiple comorbidities. A more intensified regimen warranted investigation. Cancer 2011. © 2011 American Cancer Society. |
Databáze: | OpenAIRE |
Externí odkaz: |